SI1911763T1 - Sestavki za zdravljenje gastrointestinalnih motenj - Google Patents

Sestavki za zdravljenje gastrointestinalnih motenj

Info

Publication number: SI1911763T1
Authority: SI; Slovenia
Prior art keywords: disorders; constipation; conditions; dyspepsia; functional
Prior art date: 2003-01-28

Application number

SI200431521T

Other languages

English (en)

Inventor

Mark G Currie

Shalina Mahajan-Miklos

G Todd Milne

Thea Norman

Original Assignee

Ironwood Pharmaceuticals Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-01-28

Filing date

2004-01-28

Publication date

2010-11-30

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32854294&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI1911763(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2004-01-28 Application filed by Ironwood Pharmaceuticals Inc filed Critical Ironwood Pharmaceuticals Inc

2010-11-30 Publication of SI1911763T1 publication Critical patent/SI1911763T1/sl

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
- C07K14/245—Escherichia (G)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Diabetes (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Hematology (AREA)
Urology & Nephrology (AREA)
Gastroenterology & Hepatology (AREA)
Cardiology (AREA)
Obesity (AREA)
Hospice & Palliative Care (AREA)
Heart & Thoracic Surgery (AREA)
Endocrinology (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Pulmonology (AREA)
Oncology (AREA)
Immunology (AREA)
Epidemiology (AREA)
Vascular Medicine (AREA)
Otolaryngology (AREA)

SI200431521T 2003-01-28 2004-01-28 Sestavki za zdravljenje gastrointestinalnih motenj SI1911763T1 (sl)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US44309803P	2003-01-28	2003-01-28
US47128803P	2003-05-15	2003-05-15
US51946003P	2003-11-12	2003-11-12
EP07011869A EP1911763B1 (en)	2003-01-28	2004-01-28	Compositions for the treatment of gastrointestinal disorders

Publications (1)

Publication Number	Publication Date
SI1911763T1 true SI1911763T1 (sl)	2010-11-30

Family

ID=32854294

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
SI200431918T SI2246360T1 (sl)	2003-01-28	2004-01-28	Sestavki za zdravljenje gastrointestinalnih motenj
SI200431521T SI1911763T1 (sl)	2003-01-28	2004-01-28	Sestavki za zdravljenje gastrointestinalnih motenj
SI200430401T SI1594517T1 (sl)	2003-01-28	2004-01-28	Sestavki za zdravljenje gastrointestinalnih motenj

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
SI200431918T SI2246360T1 (sl)	2003-01-28	2004-01-28	Sestavki za zdravljenje gastrointestinalnih motenj

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
SI200430401T SI1594517T1 (sl)	2003-01-28	2004-01-28	Sestavki za zdravljenje gastrointestinalnih motenj

Country Status (28)

Country	Link
US (3)	US20040266989A1 (sl)
EP (3)	EP1911763B1 (sl)
JP (3)	JP4584911B2 (sl)
KR (2)	KR101227626B1 (sl)
CN (2)	CN100589839C (sl)
AT (2)	ATE477268T1 (sl)
AU (2)	AU2004210161B2 (sl)
BE (1)	BE2013C032I2 (sl)
BR (2)	BRPI0407071B8 (sl)
CA (1)	CA2514507C (sl)
CY (5)	CY1110905T1 (sl)
DE (2)	DE602004007105T2 (sl)
DK (3)	DK1594517T3 (sl)
ES (3)	ES2285417T3 (sl)
FR (2)	FR13C0029I2 (sl)
HU (1)	HUS1300022I1 (sl)
IL (2)	IL169863A (sl)
LT (1)	LTC1594517I2 (sl)
LU (2)	LU92200I2 (sl)
MX (1)	MXPA05008097A (sl)
NL (1)	NL300593I2 (sl)
NO (3)	NO334112B1 (sl)
NZ (2)	NZ541595A (sl)
PT (3)	PT1911763E (sl)
RU (2)	RU2543350C2 (sl)
SG (2)	SG192300A1 (sl)
SI (3)	SI2246360T1 (sl)
WO (1)	WO2004069165A2 (sl)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2905585C (en)	2001-03-29	2020-02-18	Synergy Pharmaceuticals, Inc.	Guanylate cyclase receptor agonists for the treatment and/or prevention of cancer or polyps
ATE477268T1 (de)	2003-01-28	2010-08-15	Ironwood Pharmaceuticals Inc	Zusammensetzungen zur behandlung von magen-darm- störungen
US7304036B2 (en)	2003-01-28	2007-12-04	Microbia, Inc.	Methods and compositions for the treatment of gastrointestinal disorders
US20060281682A1 (en) *	2003-01-28	2006-12-14	Currie Mark G	Methods and compositions for the treatment of gastrointestinal disorders
US7371727B2 (en)	2003-01-28	2008-05-13	Microbia, Inc.	Methods and compositions for the treatment of gastrointestinal disorders
US7772188B2 (en) *	2003-01-28	2010-08-10	Ironwood Pharmaceuticals, Inc.	Methods and compositions for the treatment of gastrointestinal disorders
DK1644021T3 (da)	2003-06-13	2012-10-29	Ironwood Pharmaceuticals Inc	Fremgangsmåder og sammensætninger til behandlingen af gastrointestinale sygdomme
US7494979B2 (en) *	2003-06-13	2009-02-24	Ironwood Pharmaceuticals, Inc.	Method for treating congestive heart failure and other disorders
US20050266028A1 (en) *	2004-05-25	2005-12-01	University Of Georgia Research Foundation, Inc.	Compositions and methods for modulating an immune response
JPWO2006046746A1 (ja) *	2004-10-26	2008-05-22	味の素株式会社	内臓痛予防・治療剤
US20090253634A1 (en) *	2005-08-19	2009-10-08	Microbia, Inc.	Methods and Compositions for the Treatment of Gastrointestinal Disorders
CN105381453B9 (zh)	2005-09-29	2019-01-11	益普生制药股份有限公司	用于刺激胃肠运动性的组合物和方法
US20090305993A1 (en) *	2006-02-24	2009-12-10	Ironwood Pharmaceuticals, Inc.	Methods and composition for the treatment of gastrointestinal disorders
EP2129683A4 (en)	2007-02-26	2011-01-05	Ironwood Pharmaceuticals Inc	METHODS AND COMPOSITIONS FOR TREATMENT OF HEART FAILURE AND OTHER DISORDERS
WO2008137318A1 (en) *	2007-05-04	2008-11-13	Ironwood Pharmaceuticals, Inc.	Compositions and methods for treating disorders associated with salt or fluid retention
US8969514B2 (en)	2007-06-04	2015-03-03	Synergy Pharmaceuticals, Inc.	Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
US20100120694A1 (en)	2008-06-04	2010-05-13	Synergy Pharmaceuticals, Inc.	Agonists of Guanylate Cyclase Useful for the Treatment of Gastrointestinal Disorders, Inflammation, Cancer and Other Disorders
JP5546451B2 (ja)	2007-06-04	2014-07-09	シナジーファーマシューティカルズインコーポレイテッド	胃腸の障害、炎症、癌および他の障害の処置に有用なグアニル酸シクラーゼのアゴニスト
WO2009149278A1 (en)	2008-06-04	2009-12-10	Synergy Pharmaceuticals Inc.	Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US20110306125A1 (en) *	2008-06-30	2011-12-15	Ironwood Pharmaceuticals, Inc.	Protein Expression Methods
EP3241839B1 (en)	2008-07-16	2019-09-04	Bausch Health Ireland Limited	Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
NZ591713A (en) *	2008-08-15	2013-07-26	Ironwood Pharmaceuticals Inc	Solid stable formulations of linaclotide for oral administration
MX2011005245A (es)	2008-11-19	2011-06-17	Forest Lab Holdings Ltd	Forma cristalina de linaclotida.
US20100221329A1 (en) *	2008-12-03	2010-09-02	Synergy Pharmaceuticals, Inc.	Formulations of guanylate cyclase c agonists and methods of use
ES2439998T3 (es)	2009-04-10	2014-01-27	Corden Pharma Colorado, Inc.	Procedimiento para aislar linaclotida
JP2013501071A (ja) *	2009-08-06	2013-01-10	アイロンウッドファーマシューティカルズ，インコーポレイテッド	リナクロチドを含む処方物
WO2011020054A1 (en)	2009-08-13	2011-02-17	Ironwood Pharmaceuticals Inc.	Method for modulating the pharmacodynamic effect of orally administered guanylate cyclase receptor agonists
UY33017A (es) *	2009-11-09	2011-06-30	Ironwood Pharmaceuticals Inc	Tratamiento para trastornos gastrointestinales
CN102822194B (zh) *	2009-12-07	2016-10-26	硬木药品公司	用于胃肠病症的治疗
PL2536742T3 (pl)	2010-02-17	2017-11-30	Ironwood Pharmaceuticals, Inc.	Leczenie zaburzeń żołądkowo-jelitowych
WO2011145062A1 (en)	2010-05-21	2011-11-24	Link Research & Grants Corporation	Treatment of tinnitus and related auditory dysfunctions
WO2011156453A2 (en)	2010-06-09	2011-12-15	Combimab, Inc.	Therapeutic peptides
EP3626253B8 (en)	2010-08-11	2022-04-20	Ironwood Pharmaceuticals, Inc.	Stable formulations of linaclotide
US9616097B2 (en)	2010-09-15	2017-04-11	Synergy Pharmaceuticals, Inc.	Formulations of guanylate cyclase C agonists and methods of use
EP2621509A4 (en)	2010-09-15	2016-08-03	Synergy Pharmaceuticals Inc	FORMULATIONS OF GUANYLATE CYCLASE C AGONISTS AND METHOD OF USE
WO2012155101A1 (en)	2011-05-11	2012-11-15	Ironwood Pharmaceuticals, Inc.	Treatments for gastrointestinal disorders
US9303066B2 (en)	2011-05-11	2016-04-05	Ironwood Pharmaceuticals, Inc.	Treatments for gastrointestinal disorders
US9617305B2 (en)	2011-06-08	2017-04-11	Ironwood Pharmaceuticals, Inc.	Treatments for gastrointestinal disorders
WO2012170766A1 (en)	2011-06-08	2012-12-13	Ironwood Pharmaceuticals, Inc.	Treatments for gastrointestinal disorders
MD480Z (ro) *	2011-07-07	2012-09-30	Elvira Andon	Metoda de tratament al colitei ulceroase nespecifice acute
DK2776055T3 (en)	2011-08-17	2017-03-06	Ironwood Pharmaceuticals Inc	TREATMENTS FOR GASTROINTESTINAL DISORDERS
EA022546B1 (ru) *	2011-09-28	2016-01-29	Федеральное Государственное Бюджетное Учреждение Науки Институт Биоорганической Химии Им. Академиков М.М. Шемякина И Ю.А. Овчинникова Российской Академии Наук	Способ торможения роста карциномы эрлиха у лабораторного животного
US20140018307A1 (en) *	2012-07-12	2014-01-16	Forest Laboratories Holdings Ltd.	Linaclotide compositions
RU2528641C2 (ru) *	2012-08-22	2014-09-20	Государственное бюджетное образовательное учреждение высшего профессионального образования "Воронежская государственная медицинская академия им. Н.Н. Бурденко" Министерства здравоохранения и социального развития Российской Федерации	Способ лечения больных с синдромом диспепсии в сочетании с избыточной массой тела
CN102875655B (zh) *	2012-09-29	2014-12-17	深圳翰宇药业股份有限公司	一种合成利那洛肽的方法
US20150361139A1 (en)	2013-01-30	2015-12-17	Sandoz Ag	Crystalline form of linaclotide
HK1220696A1 (zh)	2013-03-15	2017-05-12	Bausch Health Ireland Limited	鸟苷酸环化酶激动剂及其用途
JP6694385B2 (ja)	2013-08-09	2020-05-13	アーデリクス，インコーポレーテッド	リン酸塩輸送阻害のための化合物及び方法
CN114716514A (zh) *	2015-05-01	2022-07-08	硬木药品公司	用于结肠清洁和胃肠病症治疗的组合物
EP3430056A4 (en) *	2016-03-15	2019-11-20	The Regents of the University of California	METHOD AND COMPOSITIONS FOR THE TREATMENT AND PREVENTION OF ALPHA-8-BETA-1-INTEGRIN ASSOCIATED DISEASES
CN107929718A (zh) *	2017-10-19	2018-04-20	南京星银药业集团有限公司	Glp‑1类似物及gc‑c受体激动剂组合物缓释制剂及其制备方法
WO2020082168A1 (en) *	2018-10-23	2020-04-30	Abk Biomedical Incorporated	Delivery device
CN109467606A (zh) *	2018-11-15	2019-03-15	大连理工大学	一种大肠杆菌肠毒素STa-LTB-STb融合蛋白及其编码基因和应用
EP3972599B1 (en)	2019-05-21	2025-10-22	Ardelyx, Inc.	Combination for lowering serum phosphate in a patient
RU2712761C1 (ru) *	2019-07-02	2020-01-31	Федеральное государственное бюджетное научное учреждение "Томский национальный исследовательский медицинский центр Российской академии наук" (Томский НИМЦ)	Средство для стимуляции регенерации эндотелия легких при сочетании метаболического синдрома и хронической обструктивной болезни легких
CN111265653B (zh) *	2020-02-09	2023-05-09	华中科技大学同济医学院附属协和医院	心房利钠肽在制备炎症性肠病治疗药物中的应用
WO2021191865A1 (en) *	2020-03-26	2021-09-30	Dusa Pharmaceuticals, Inc.	Management of dermal neurofibromatosis lesions
WO2023144292A1 (en)	2022-01-28	2023-08-03	Fresenius Kabi Ipsum S.R.L.	Process for the preparation of linaclotide
WO2025207484A1 (en) *	2024-03-25	2025-10-02	Merveille.Ai	Use of aprepitant and cyclic dipeptide for weight control

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US73628A (en) *		1868-01-21		mitchell
US258687A (en) *		1882-05-30		Grain-binder
US32684A (en) *		1861-07-02		Stump-extkactob
US232013A (en) *		1880-09-07		Henry h
US121961A (en) *		1871-12-19		Improvement in devices for supporting pipe-cores
US266989A (en) *		1882-11-07		Automatic fire
US152868A (en) *		1874-07-07		Improvement in type-setting machines
US3773919A (en)	1969-10-23	1973-11-20	Du Pont	Polylactide-drug mixtures
IE52535B1 (en)	1981-02-16	1987-12-09	Ici Plc	Continuous release pharmaceutical compositions
US6342373B1 (en) *	1983-11-21	2002-01-29	Ucp Gen-Pharma Ag	Process for preparing recombinant eglin, protease inhibitor
IT1217123B (it)	1987-02-05	1990-03-14	Rotta Research Lab	Derivati otticamente attivi dell acido 5 pentilammino 5 oxo pentanoico r ad attivita antagonista della colecistochinina e procedimento per la loro preparazione
GB2209937B (en)	1987-09-21	1991-07-03	Depiopharm S A	Water insoluble polypeptides
CH679207A5 (sl)	1989-07-28	1992-01-15	Debiopharm Sa
CA2046830C (en)	1990-07-19	1999-12-14	Patrick P. Deluca	Drug delivery system involving inter-action between protein or polypeptide and hydrophobic biodegradable polymer
HUT64023A (en)	1991-03-22	1993-11-29	Sandoz Ag	Process for producing aminoguanidine derivatives and pharmaceutical compositions comprising such compounds
FR2674849B1 (fr)	1991-04-02	1994-12-23	Logeais Labor Jacques	Nouveaux derives de n-cyclohexyl benzamides ou thiobenzamides, leurs preparations et leurs applications en therapeutique.
CH683149A5 (fr)	1991-07-22	1994-01-31	Debio Rech Pharma Sa	Procédé pour la préparation de microsphères en matériau polymère biodégradable.
US5140102A (en)	1991-09-23	1992-08-18	Monsanto Company	Pentadecapeptide, guanylin, which stimulates intestinal guanylate cyclase
US5824645A (en)	1991-12-30	1998-10-20	Neurex Corporation	Method of treating inflammation
CA2151741C (en)	1991-12-30	2001-12-11	Alan Justice	Methods of producing analgesia and enhancing opiate analgesia
GB9211268D0 (en)	1992-05-28	1992-07-15	Ici Plc	Salts of basic peptides with carboxyterminated polyesters
US5969097A (en) *	1992-06-23	1999-10-19	G. D. Searle & Co.	Human guanylin
US5672659A (en)	1993-01-06	1997-09-30	Kinerton Limited	Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides
DE69432459T2 (de)	1993-01-06	2003-11-27	Kinerton Ltd., Blanchardstown	Ionische molekularkonjugate von bioabbaubaren polyestern und bioaktiven polypeptiden
US5395490A (en) *	1993-05-14	1995-03-07	Intertec, Ltd.	Method for treating materials by the application of electromagnetic energy at resonant absorption frequencies
JP4194113B2 (ja) *	1993-10-26	2008-12-10	トーマス・ジェファーソン・ユニバーシティ	結腸直腸癌細胞に特異的に結合する組成物およびその使用方法
US5489670A (en) *	1993-10-29	1996-02-06	G. D. Searle & Co.	Human uroguanylin
US5610145A (en)	1994-04-15	1997-03-11	Warner-Lambert Company	Tachykinin antagonists
US5612052A (en)	1995-04-13	1997-03-18	Poly-Med, Inc.	Hydrogel-forming, self-solvating absorbable polyester copolymers, and methods for use thereof
ATE359086T1 (de)	1995-06-27	2007-05-15	Eisai R&D Man Co Ltd	Zusammensetzungen zur erzielung von analgesie und zur hemmung der progression neuropathischer schmerzerkrankungen
US5795864A (en)	1995-06-27	1998-08-18	Neurex Corporation	Stable omega conopetide formulations
US6054429A (en)	1996-03-08	2000-04-25	Elan Pharmaceuticals, Inc.	Epidural method of producing analgesia
GB9524104D0 (en)	1995-11-24	1996-01-24	Smithkline Beecham Spa	Novel compounds
EA002124B1 (ru)	1995-11-24	2001-12-24	Смитклайн Бичам С.П.А.	Производные хинолина
DE69731623D1 (de)	1996-04-23	2004-12-23	Ipsen Mfg Ireland Ltd	Saure Polymilchsäure Polymere
US6589750B2 (en)	1997-02-20	2003-07-08	Institut Pasteur	Therapeutic use of the SMR1 protein, the SMR1 maturation products, specifically the QHNPR pentapeptide as well as its biologically active derivatives
JP2001513097A (ja)	1997-02-28	2001-08-28	ビイクグルデンロンベルクヒエーミツシエフアブリークゲゼルシヤフトミツトベシユレンクテルハフツング	Ｐｄｅ−抑制物質とアデニル酸シクラーゼ・アゴニストもしくはグアニル酸シクラーゼ・アゴニストとからなる相乗的組み合わせ組成物
US5893985A (en)	1997-03-14	1999-04-13	The Lincoln Electric Company	Plasma arc torch
NZ329807A (en)	1997-04-23	2000-07-28	Pfizer	NK-1 receptor antagonists and P receptor antagonists 2-Diarylmethyl-3-amino-1-azabicyclo[2.2.2]octane derivatives and amino substituted N-containing rings as agents for treating irritable bowel syndrome
ATE273996T1 (de)	1997-09-12	2004-09-15	Pharis Biotec Gmbh	Zusammensetzung zur therapie von diabetes mellitus und fettsucht
US20010006972A1 (en)	1998-04-21	2001-07-05	Stephen A. Williams	Nk-1 receptor antagonists for the treatment of symptoms of irritable bowel syndrome
IT1304152B1 (it)	1998-12-10	2001-03-08	Mediolanum Farmaceutici Srl	Composizioni comprendenti un peptide ed acido polilattico-glicolicoatte alla preparazione di impianti sottocutanei aventi un prolungato
CN1189211C (zh)	1999-06-23	2005-02-16	巴斯德研究所	用于治疗人际关系异常和行为障碍的治疗方法和组合物
IL147802A0 (en)	1999-08-18	2002-08-14	Sod Conseils Rech Applic	Sustained release formulation of a peptide
SE9903291D0 (sv)	1999-09-15	1999-09-15	Astra Ab	New process
JP2003516316A (ja)	1999-10-06	2003-05-13	ファルマシアコーポレイション	腸癌阻止剤としてのウログアニリン
EP1225897B1 (en)	1999-11-01	2004-09-08	RHODES, John	Composition for treatment of constipation and irritable bowel syndrome
AUPQ514600A0 (en)	2000-01-18	2000-02-10	James Cook University	Brain injury treatment
WO2001064212A1 (en)	2000-03-01	2001-09-07	University College London	Modulators of the endocannabinoid uptake and of the vallinoid receptors
EP1216707B1 (en)	2000-12-22	2005-02-09	Institut Pasteur	Process for screening ligand molecules that specifically bind to the NEP binding site for the QHNPR pentapeptide
JP2004521123A (ja)	2001-02-02	2004-07-15	ファルマシア・コーポレーション	腸癌阻害のためのウログアニリンおよびシクロオキシゲナーゼ−２阻害薬の組合わせ
CA2905585C (en)	2001-03-29	2020-02-18	Synergy Pharmaceuticals, Inc.	Guanylate cyclase receptor agonists for the treatment and/or prevention of cancer or polyps
EP1451211A2 (en)	2001-03-30	2004-09-01	University of Copenhagen	Compositions and methods for modulating guanylyl cyclase signaling receptor (gc-c) activity and for treating meniere's disease
MY134211A (en)	2001-05-18	2007-11-30	Smithkline Beecham Corp	Novel use
EP1392729A2 (de)	2001-06-05	2004-03-03	Yalcin Cetin	Verwendung eines peptids, welches guanylat cyclase c aktiviert, für die behandlung von atemwegserkrankungen über die luftwege, arzneimittel, inhalationsvorrichtung und diagnoseverfahren
FR2830451B1 (fr)	2001-10-09	2004-04-30	Inst Nat Sante Rech Med	Utilisation de peptides analogues de la thymuline(pat)pour la fabrication de medicaments contre la douleur
EP1321142A1 (en)	2001-12-21	2003-06-25	Novartis AG	Solid pharmaceutical composition for oral administration of Tegaserod
US20040121961A1 (en)	2002-02-04	2004-06-24	Jaime Masferrer	Uroguanylin and cyclooxygenase-2 inhibitor combinations for inhibition of intestinal cancer
US20030232013A1 (en)	2002-02-22	2003-12-18	Gary Sieckman	Therapeutic and diagnostic targeting of cancers cells with tumor homing peptides
EP1531846A4 (en)	2002-02-27	2006-04-19	Us Gov Health & Human Serv	Conjugates of ligand, linker and cytotoxic agent and related compositions and methods of use
PL223471B1 (pl)	2002-03-15	2016-10-31	Cypress Bioscience Inc	Kompozycja farmaceutyczna zawierająca milnacypran do stosowania w leczeniu zespołu nadwrażliwości jelita grubego
JP2005531557A (ja)	2002-05-17	2005-10-20	メルク　パテント　ゲゼルシャフト　ミット　ベシュレンクテル　ハフトング	選択的オピエート受容体モジュレーターとして効果的な化合物の使用
US7304036B2 (en)	2003-01-28	2007-12-04	Microbia, Inc.	Methods and compositions for the treatment of gastrointestinal disorders
ATE477268T1 (de) *	2003-01-28	2010-08-15	Ironwood Pharmaceuticals Inc	Zusammensetzungen zur behandlung von magen-darm- störungen
US7772188B2 (en)	2003-01-28	2010-08-10	Ironwood Pharmaceuticals, Inc.	Methods and compositions for the treatment of gastrointestinal disorders
US7371727B2 (en)	2003-01-28	2008-05-13	Microbia, Inc.	Methods and compositions for the treatment of gastrointestinal disorders
US20060281682A1 (en)	2003-01-28	2006-12-14	Currie Mark G	Methods and compositions for the treatment of gastrointestinal disorders
EP1599165A4 (en)	2003-02-10	2010-09-08	Univ Jefferson	THE USE OF GCC LIGANDS
US20090253634A1 (en) *	2005-08-19	2009-10-08	Microbia, Inc.	Methods and Compositions for the Treatment of Gastrointestinal Disorders

2004
- 2004-01-28 AT AT07011869T patent/ATE477268T1/de active
- 2004-01-28 JP JP2006503109A patent/JP4584911B2/ja not_active Expired - Lifetime
- 2004-01-28 EP EP07011869A patent/EP1911763B1/en not_active Expired - Lifetime
- 2004-01-28 SI SI200431918T patent/SI2246360T1/sl unknown
- 2004-01-28 ES ES04706011T patent/ES2285417T3/es not_active Expired - Lifetime
- 2004-01-28 SI SI200431521T patent/SI1911763T1/sl unknown
- 2004-01-28 PT PT07011869T patent/PT1911763E/pt unknown
- 2004-01-28 DE DE602004007105T patent/DE602004007105T2/de not_active Expired - Lifetime
- 2004-01-28 KR KR1020057013966A patent/KR101227626B1/ko not_active Expired - Lifetime
- 2004-01-28 MX MXPA05008097A patent/MXPA05008097A/es active IP Right Grant
- 2004-01-28 NZ NZ541595A patent/NZ541595A/en not_active IP Right Cessation
- 2004-01-28 WO PCT/US2004/002390 patent/WO2004069165A2/en not_active Ceased
- 2004-01-28 BR BRPI0407071A patent/BRPI0407071B8/pt not_active IP Right Cessation
- 2004-01-28 DK DK04706011T patent/DK1594517T3/da active
- 2004-01-28 KR KR1020117019764A patent/KR101227627B1/ko not_active Expired - Lifetime
- 2004-01-28 SI SI200430401T patent/SI1594517T1/sl unknown
- 2004-01-28 AT AT04706011T patent/ATE365174T1/de active
- 2004-01-28 AU AU2004210161A patent/AU2004210161B2/en active Active
- 2004-01-28 PT PT04706011T patent/PT1594517E/pt unknown
- 2004-01-28 DK DK07011869.0T patent/DK1911763T3/da active
- 2004-01-28 SG SG2012003802A patent/SG192300A1/en unknown
- 2004-01-28 BR BR122018074353A patent/BR122018074353B8/pt active IP Right Grant
- 2004-01-28 CA CA2514507A patent/CA2514507C/en not_active Expired - Lifetime
- 2004-01-28 EP EP10170038A patent/EP2246360B1/en not_active Expired - Lifetime
- 2004-01-28 US US10/766,735 patent/US20040266989A1/en not_active Abandoned
- 2004-01-28 CN CN200480008533A patent/CN100589839C/zh not_active Expired - Lifetime
- 2004-01-28 CN CN2009102662250A patent/CN101787073B/zh not_active Expired - Lifetime
- 2004-01-28 EP EP04706011A patent/EP1594517B1/en not_active Expired - Lifetime
- 2004-01-28 SG SG200705302-8A patent/SG168407A1/en unknown
- 2004-01-28 PT PT10170038T patent/PT2246360E/pt unknown
- 2004-01-28 DK DK10170038.3T patent/DK2246360T3/da active
- 2004-01-28 ES ES10170038T patent/ES2387848T3/es not_active Expired - Lifetime
- 2004-01-28 RU RU2008147983/15A patent/RU2543350C2/ru active
- 2004-01-28 NZ NZ570134A patent/NZ570134A/en not_active IP Right Cessation
- 2004-01-28 ES ES07011869T patent/ES2350123T3/es not_active Expired - Lifetime
- 2004-01-28 RU RU2005127058/15A patent/RU2353383C2/ru active
- 2004-01-28 DE DE602004028678T patent/DE602004028678D1/de not_active Expired - Lifetime
2005
- 2005-07-25 IL IL169863A patent/IL169863A/en active IP Right Grant
- 2005-08-18 NO NO20053864A patent/NO334112B1/no not_active IP Right Cessation
2007
- 2007-08-09 CY CY20071101072T patent/CY1110905T1/el unknown
- 2007-10-31 US US11/930,696 patent/US7704947B2/en not_active Expired - Lifetime
2009
- 2009-11-10 AU AU2009235993A patent/AU2009235993B2/en active Active
2010
- 2010-04-05 US US12/754,138 patent/US8080526B2/en not_active Expired - Lifetime
- 2010-06-22 JP JP2010141519A patent/JP5563384B2/ja not_active Expired - Lifetime
- 2010-11-04 CY CY20101101000T patent/CY1111058T1/el unknown
2012
- 2012-08-09 IL IL221380A patent/IL221380A0/en active IP Right Grant
- 2012-09-19 CY CY20121100859T patent/CY1113217T1/el unknown
2013
- 2013-02-28 JP JP2013038602A patent/JP5748791B2/ja not_active Expired - Lifetime
- 2013-04-05 NO NO20130460A patent/NO336768B1/no not_active IP Right Cessation
- 2013-05-22 LT LTPA2013013C patent/LTC1594517I2/lt unknown
- 2013-05-22 HU HUS1300022 patent/HUS1300022I1/hu unknown
- 2013-05-22 NL NL300593C patent/NL300593I2/nl unknown
- 2013-05-22 LU LU92200C patent/LU92200I2/fr unknown
- 2013-05-22 LU LU92201C patent/LU92201I2/fr unknown
- 2013-05-23 FR FR13C0029C patent/FR13C0029I2/fr active Active
- 2013-05-23 FR FR13C0030C patent/FR13C0030I1/fr active Active
- 2013-05-24 BE BE2013C032C patent/BE2013C032I2/nl unknown
- 2013-05-24 CY CY2013021C patent/CY2013021I2/el unknown
2014
- 2014-05-21 NO NO2014013C patent/NO2014013I1/no unknown
2025
- 2025-01-28 CY CY2013022C patent/CY2013022I1/el unknown

Also Published As

Publication number	Publication date
HK1078768A1 (en)	2006-03-24
CA2514507C (en)	2012-03-20
FR13C0030I1 (fr)	2013-07-05
US8080526B2 (en)	2011-12-20
ES2285417T3 (es)	2007-11-16
WO2004069165A2 (en)	2004-08-19
SG168407A1 (en)	2011-02-28
EP2246360B1 (en)	2012-06-27
WO2004069165A3 (en)	2005-03-17
CN1795007A (zh)	2006-06-28
CY2013021I1 (el)	2020-05-29
BR122018074353B1 (pt)	2019-07-16
BRPI0407071B8 (pt)	2021-05-25
ATE477268T1 (de)	2010-08-15
JP2006516631A (ja)	2006-07-06
LU92200I2 (fr)	2024-03-21
SI2246360T1 (sl)	2012-10-30
CY2013022I1 (el)	2020-05-29
ES2350123T3 (es)	2011-01-18
CA2514507A1 (en)	2004-08-19
KR101227627B1 (ko)	2013-01-31
RU2353383C2 (ru)	2009-04-27
CN101787073A (zh)	2010-07-28
US20040266989A1 (en)	2004-12-30
SG192300A1 (en)	2013-08-30
US20110124583A1 (en)	2011-05-26
CY2013021I2 (el)	2025-07-04
MXPA05008097A (es)	2006-02-08
JP2013116910A (ja)	2013-06-13
RU2014153593A3 (sl)	2018-08-06
NL300593I2 (nl)	2020-04-15
LU92200I1 (fr)	2020-06-02
ES2387848T3 (es)	2012-10-02
CY1110905T1 (el)	2015-06-10
PT1594517E (pt)	2007-07-20
EP1911763A3 (en)	2008-06-25
LU92201I2 (fr)	2013-11-22
NO20130460L (no)	2005-10-26
CY1111058T1 (el)	2015-06-11
DK1594517T3 (da)	2007-10-29
JP5563384B2 (ja)	2014-07-30
PT2246360E (pt)	2012-08-31
AU2004210161B2 (en)	2009-11-26
IL221380A0 (en)	2012-09-24
RU2008147983A (ru)	2010-06-10
AU2009235993B2 (en)	2013-07-04
DK2246360T3 (da)	2012-08-13
BRPI0407071A (pt)	2006-01-24
BR122018074353B8 (pt)	2023-05-02
EP1911763A2 (en)	2008-04-16
IL169863A (en)	2012-10-31
JP2010222377A (ja)	2010-10-07
BE2013C032I2 (sl)	2023-08-22
CN101787073B (zh)	2013-12-25
AU2004210161A1 (en)	2004-08-19
EP1594517A2 (en)	2005-11-16
KR20050106404A (ko)	2005-11-09
FR13C0029I1 (fr)	2013-07-05
RU2005127058A (ru)	2006-03-10
NO20053864L (no)	2005-10-26
US7704947B2 (en)	2010-04-27
NO2014013I2 (no)	2014-05-21
EP1594517A4 (en)	2006-03-29
KR101227626B1 (ko)	2013-02-01
NO2014013I1 (no)	2014-06-02
PT1911763E (pt)	2010-11-18
ATE365174T1 (de)	2007-07-15
AU2009235993A1 (en)	2009-11-26
HUS1300022I1 (hu)	2019-11-28
NO20053864D0 (no)	2005-08-18
JP5748791B2 (ja)	2015-07-15
RU2763796C2 (ru)	2022-01-11
RU2543350C2 (ru)	2015-02-27
EP2246360A1 (en)	2010-11-03
LTC1594517I2 (lt)	2020-03-10
DE602004007105D1 (de)	2007-08-02
CN100589839C (zh)	2010-02-17
NO334112B1 (no)	2013-12-09
DK1911763T3 (da)	2010-11-15
RU2014153593A (ru)	2016-07-20
DE602004007105T2 (de)	2008-02-28
SI1594517T1 (sl)	2007-10-31
FR13C0029I2 (fr)	2024-04-19
NO336768B1 (no)	2015-11-02
NZ541595A (en)	2008-08-29
US20090005534A1 (en)	2009-01-01
DE602004028678D1 (de)	2010-09-23
CY1113217T1 (el)	2016-04-13
KR20110114682A (ko)	2011-10-19
NL300593I1 (nl)	2015-10-21
EP1911763B1 (en)	2010-08-11
JP4584911B2 (ja)	2010-11-24
BRPI0407071B1 (pt)	2019-02-12
EP1594517B1 (en)	2007-06-20
NZ570134A (en)	2010-02-26

Publication	Publication Date	Title
SI1911763T1 (sl)	2010-11-30	Sestavki za zdravljenje gastrointestinalnih motenj
SG153824A1 (en)	2009-07-29	Methods and compositions for the treatment of gastrointestinal disorders
WO2007022531A3 (en)	2008-01-24	Methods and compositions for the treatment of gastrointestinal disorders
WO2005016244A3 (en)	2005-10-20	Methods and compositions for the treatment of gastrointestinal disorders
WO2006086653A3 (en)	2007-12-06	Methods and compositions for the treatment of gastrointestinal disorders
WO2008002971A3 (en)	2008-08-28	Methods and compositions for the treatment of gastrointestinal disorders
WO2007101158A3 (en)	2008-05-02	Methods and compositions for the treatment of gastrointestinal disorders
EA201290799A1 (ru)	2013-03-29	Лечение желудочно-кишечных расстройств
DE602004016499D1 (de)	2008-10-23	Zusammensetzungen und verfahren zur behandlung von entzündlicher darmerkrankung
WO2005074575A3 (en)	2006-06-22	Methods and compositions for the treatment of gastrointestinal disorders
WO2007062168A3 (en)	2007-12-06	Methods and compositions for the treatment of gastrointestinal disorders
CY1113569T1 (el)	2016-06-22	Μεθοδοι και συνθεσεις για την αγωγη γαστρεντερικων διαταραχων